• In early June 2026, Johnson & Johnson reported a series of positive late-stage data readouts and regulatory advances across its immunology and oncology pipeline, including Phase 2 nipocalimab results in lupus and Sjögren’s disease, strong MajesTEC-9 outcomes for TECVAYLI in multiple myeloma, and an FDA label expansion for TREMFYA in psoriatic arthritis.
• These outcomes highlight Johnson & Johnson’s broad, late-stage innovation across autoimmune and cancer indications, reinforcing its efforts to replace revenue at risk from products facing biosimilar competition.
• We’ll now examine how this wave of late-stage successes, particularly nipocalimab’s progress across multiple autoimmune diseases, affects Johnson & Johnson’s investment narrative.

AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Johnson & Johnson Investment Narrative Recap

To own Johnson & Johnson today, you need to believe its drug and MedTech pipeline can more than offset pressure from biosimilars, tariffs and ongoing talc litigation, while supporting its long dividend history. The latest oncology and immunology readouts strengthen the case that late stage assets can help refill revenue once STELARA erosion fully shows up, but they do not change the fact that talc outcomes and MedTech pricing in China remain the near term swing factors for the stock.

Among the new data, TECVAYLI’s MajesTEC 9 results stand out for investors. The study showed meaningful progression free and overall survival benefits versus standard regimens in earlier line multiple myeloma, reinforcing J&J’s bet that its oncology portfolio can carry more weight as STELARA and other legacy drugs face biosimilar and pricing pressure. If regulators clear broader TECVAYLI use, it could become one of the more important levers behind the company’s medium term growth targets.

Yet against this optimism, investors should also weigh how talc litigation and tariff related MedTech costs could still reshape the story...

Johnson & Johnson's narrative projects $116.6 billion revenue and $26.9 billion earnings by 2029. This requires 6.6% yearly revenue growth and about a $5.9 billion earnings increase from $21.0 billion today.

Uncover how Johnson & Johnson's forecasts yield a $252.87 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Before this news, the most pessimistic analysts expected J&J’s earnings to fall to about US$21.9 billion by 2029, even as late stage oncology and immunology assets gained traction, so this new data could push those views closer to or further from reality depending on how you see the trade off between pipeline success and execution risks.

Explore 7 other fair value estimates on Johnson & Johnson - why the stock might be worth as much as 61% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Johnson & Johnson research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Johnson & Johnson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Johnson & Johnson's overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.